Eppendorf Provides Master cycler X40 to raise Laboratory Quality

India Pharma Outlook Team | Friday, 03 November 2023

 India Pharma Outlook Team

Eppendorf, the renowned life science company, specializes in the development and sale of cutting-edge instruments, consumables, and services catered towards liquid handling, sample handling, and cell handling in laboratories worldwide. Their newest addition to the product lineup, the Mastercycler X40, is specifically designed to provide convenient support for daily laboratory routines.

By using this product, daily laboratory routines will not just be reliable and efficient, but also significantly enhanced. Now available for every laboratory task is our new product, equipped with a thermal cycler of exceptional quality and proven reliability. Introducing the Mastercycler X40 - Unveiling a new era of excellence in laboratory work with its numerous advantages. In order to ensure effective operation of the Master cycler X40 PCR cycler, two critical requirements must be met: reproducible nucleic acid amplification and consistent temperature homogeneity .

The new Master cycler X40 raises the standard in PCR with its intuitive touch-screen user interface and ergonomic one-hand operation . You have the freedom to use either 0.1 mL or 0.2 mL tubes or tube strips, and any type of 96-well PCR plate of your choice. With the SafeLid, your samples are protected from evaporation. The PCR protocol can be optimized effectively by utilizing the 12-column gradient to adjust temperature steps, as per pharmabiz. When you transfer protocols from slower cycler models to the Mastercycler X40, you can take advantage of the convenient programme migration feature. This feature automatically adjusts the ramp rates to align with the well-established PCR protocol, ensuring the exact same runtime. The Mastercycler X40 can be conveniently linked with our VisioNize Lab Suite to facilitate monitoring, audit trails, and documentation for a seamless digital laboratory experience in the Future.

© 2024 India Pharma Outlook. All Rights Reserved.